The effects of ALS (anti-lymphocyte serum) and NRS (normal rabbit serum) treatments on the development of malignant lymphoma, lung, subcutaneous and skin tumors induced in mice by 7,12-dimethylbenz (a) anthracene (DMBA) are described. Groups of Charles-River mice, injected at birth with a dose of 100 μg of DMBA, received a single injection of ALS or NRS at the same time as DMBA administration or 10, 20, 30, 40 and 50 days after birth. Incidence, latency, histology and spread of the tumors were studied in all groups. It was found that both ALS and NRS increased tumor incidence and shortened their latency period. Malignant lymphomas were the main tumors whose latency was shortened either by ALS or NRS treatment. In addition ALS treatment apparently increased dissemination of DMBA induced lymphoma in bone marrow.
Get full access to this article
View all access options for this article.
References
1.
AllisonA. C.: Tumour development following immunosuppression. Proc. Roy. Soc. Med., 63: 1077–1080, 1970.
2.
AllisonA. C., BermanL. D., and LeveyR. H.: Increased tumour induction by adenovirus type 12 in thymectomized mice and mice treated with anti-lymphocyte serum. Nature, 215: 185–187, 1967.
3.
BallJ. K.: Immunosuppression and carcinogenesis: contrasting effects with 7,12-dimethylbenz(a)anthracene, benz(a)pyrene, and 3-methylcholanthrene. J. Nat. Cancer Inst., 44: 1–10, 1970.
4.
BallJ. K., SinclairS. R., and McCarterJ. A.: Prolonged immunosuppression by a chemical carcinogen injected at birth. Science, 152: 650–651, 1966.
5.
BalnerH., and DersjantH.: Increased oncogenic effect of methylcholanthrene after treatment with anti-lymphocyte serum. Nature, 224: 376–378, 1969.
6.
BaroniC., BertoliG., e FabrisN.: Risposta immunitaria primaria in topi di ceppo albino iniettati alla nascita con un'unica dose di 7,12-dimetilbenz(a)antracene. Tumori, 54: 117–126, 1968.
7.
BaroniC. D., BertoliG., PesandoP., and ScelsiR.: Delayed hypersensitivity in BALB/c and Charles-River mice injected at birth with a single dose of 7,12-dimethylbenz(a)anthracene (DMBA). Experientia, 26: 899–900, 1970.
8.
BaroniC. D., KimballJ. W., WardE. N., and WagarR. D.: A histological and immunological study of the effect of rabbit anti-mouse lymphocyte serum (ALS) in BALB/c mice. Transplantation, 7: 303–314, 1969.
9.
BaroniC. D., ScelsiR., PesandoP. C., e MingazziniP.: Risposta immunitaria secondaria anti-eritrociti di montone in topi Swiss iniettati alla nascita con una unica dose di 7,12-dimetilbenz(a)antracene. Tumori, 56: 269–278, 1970.
BursteinN. A., and AllisonA. C.: Effect of antilymphocytic serum on the appearance of reticular neoplasms in SJL/J mice. Nature, 225: 1139–1140, 1970.
12.
FisherE. R., SolimanO., and FisherB.: Effect of antilymphocyte serum on parameters of growth of MCA-induced tumours. Nature, 221: 287–288, 1969.
13.
Haran-GheraN., and LurieM.: Effect of heterologous antithymocyte serum on mouse skin tumorigenesis. J. Nat. Cancer Inst., 46: 103–112, 1971.
14.
HirschM.S., and MurphyF. A.: Effects of anti-thymocyte serum on Rauscher virus infection of mice. Nature, 218: 478–479, 1968.
15.
JamesK., and MilneI.: The effect of antilymphocytic antibody on the primary immune response of mice to sheep erythrocytes, bovile serum albumin, and Type III pneumococcus polysaccharide. Transplantation, 12: 109–113, 1971.
16.
JerneN. K., NordinA. A., and HenryC.: The agar plaque technique for recognizing antibody-producing cells. In: Cell-bound antibodies (AmosB., and KoprowskyH. Eds.). Wistar Inst. Symp. Monograph No. 3, p. 109–122. Philadelphia, Wistar Inst. Press, 1963.
17.
LawL. W., TingR. C., and AllisonA. C.: Effects of antilymphocyte serum on induction of tumours and leukaemia by murine sarcoma virus. Nature, 220: 611–612, 1968.
18.
LeveyR. H., and MedawarP. B.: Some experiments on the action of antilymphoid antisiera. Ann. N. Y. Acad. Sci., 129: 164–177, 1966.
19.
LeveyR. H., and MedawarP. B.: Nature and mode of action of antilymphocytic antiserum. Proc. Nat. Acad. Sci., USA, 56: 1130–1137, 1966.
20.
RabbatA. G., and JeejebhoyH. F.: Heterologous antilymphocyte serum (ALS) hastens the appearance of methylcholanthrene-induced tumors in mice. Transplantation, 9: 164–166, 1970.
21.
RappaportH., and BaroniC.: A study of the pathogenesis of malignant lymphomas induced in the Swiss mouse by 7,12-dimethylbenz(a)anthracene injected at birth. Cancer Res., 22: 1067–1074, 1962.
22.
RusseH. P., and CrowleA. J.: A comparison of thymectomized and anti-thymocyte serum-treated mice in their development of hypersensitivity to protein antigens. J. Immunol., 94: 74, 1965.
23.
StjernswärdJ.: Effect of Bacillus Calmette-Guérin and/or methylcholanthrene on the antibody-forming cells measured at the cellular level by a hemolytic plaque test. Cancer Res., 26: 1591–1594, 1966.
24.
StjernswärdJ.: Age-dependent tumor-host barrier and effect of carcinogen-induced immunodepression on rejection of isografted methylcholanthrene-induced sarcoma cells. J. Nat. Cancer Inst., 37: 505–512, 1966.
25.
StjernswärdJ.: Further immunological studies of chemical carcinogens. J. Nat. Cancer Inst., 38: 515–526, 1967.
26.
StjernswärdJ.: Immune status of the primary host toward its own methylcholanthrene-induced sarcomas. J. Nat. Cancer Inst., 40: 13–22, 1968.
27.
VandeputteM.: Antilymphocytic serum and polyoma oncogenesis in rats. Transplantation Proc., 1: 100–105, 1969.
28.
WagnerJ. L., and HanghtonG.: Immunosuppression by antilymphocyte serum and its effect on tumors induced by 3-methylcholanthrene in mice. J. Nat. Cancer Inst., 46: 1–10, 1971.
29.
WoodruffM. F. A., and AndersonN. F.: The effect of lymphocyte depletion by thoracic duct fistula and administration of antilymphocytic serum on the survival skin homografts in rats. Ann. N. Y. Acad. Sci., 120: 119–128, 1964.
30.
WoodsD. A.: Influence of antilymphocyte serum on DMBA induction of oral carcinomas. Nature, 224: 276–277, 1969.
